Choriocarcinoma. A model for tumour markers

Area of Science:

• Oncology
• Biochemistry
• Reproductive Endocrinology

Background:

• Human chorionic gonadotrophin (hCG) is a key tumor marker.
• Gestational choriocarcinoma shows hCG as an ideal indicator of tumor activity.
• Accurate interpretation of hCG assays requires understanding its complexity.

Purpose of the Study:

• To elucidate the complexities of hCG assays and their interpretation.
• To highlight the importance of understanding hCG-producing tumor pathology and natural history.
• To emphasize the role of hCG in managing a spectrum of related lesions.

Main Methods:

• Distinguishing hCG from luteinizing hormone (LH) using anti-hCG beta subunit antisera.
• Utilizing monoclonal antibodies to identify various hCG fragments in assays.
• Analyzing the spectrum of hCG-producing lesions, including self-terminating, premalignant, and malignant types.

Main Results:

• hCG assays measure a complex mixture of hCG fragments, not just intact hCG.
• hCG-producing lesions vary from self-limiting to chemotherapy-responsive or refractory.
• hCG measurements are fundamental for screening, diagnosis, prognostication, and monitoring in hydatidiform mole patients.

Conclusions:

• Awareness of hCG assay complexity and tumor pathology is essential for correct interpretation.
• hCG plays a unique and critical role in the diagnosis, management, and follow-up of hCG-producing tumors.
• Proper understanding of hCG metabolism and excretion is vital for clinical decision-making.